Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

May

15

Exagen Inc. Reports First Quarter 2023 Results

Record Physician Demand for AVISE® CTD SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN)(“Exagen”), a...

20

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

Record AVISE® CTD Volume in 2022 SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a...

23

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions,...

14

Exagen Inc. Reports Third Quarter 2022 Results

Medicare Reimbursement Returns SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of...

17

Exagen Announces Appointment of John Aballi as CEO

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN) announced today that the company has...

4

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

Dr. Concoff to lead rheumatoid arthritis medical initiatives SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) —...

4

Exagen Inc. Reports Second Quarter 2022 Results

Records in AVISE® CTD Volume, Ordering Healthcare Providers and Adopters SAN DIEGO, Aug. 04, 2022 (GLOBE...

5

Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility

AVISE® Lupus more clinically effective than current standard of care SAN DIEGO, July 05, 2022 (GLOBE...

9

Exagen Inc. Expands Coverage with MediNcrease

SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

16

Exagen Inc. Expands Coverage with Alivio Health

Partnership to provide more accurate diagnostic testing with AVISE® CTD and AVISE® Lupus SAN...

11

Exagen Inc. Reports First Quarter 2022 Results

Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CTD Monthly...

11

Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

Recent developments

News

May

15

Exagen Inc. Reports First Quarter 2023 Results

March

20

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

January

23

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

November

14